세계 의약품 첨가제 시장 규모는 2023년에 91억 8,000만 달러이며, 2030년까지 141억 2,000만 달러에 달할 것으로 예측되며, 2024-2030년의 예측 기간에 CAGR로 6.43%의 성장이 예상됩니다. 시장은 투자에 의한 의약품 제조에 대한 수요 증가, 의약품의 연구 개발에 있어서의 최신 기술 혁신, 바이오테크놀러지 기업이나 제약 기업에 있어서의 첨가제의 제품 개발 활동의 활성화 등에 의해 크게 성장하고 있으며, 이들이 2024-2030년에 의약품 첨가제 시장을 견인할 것으로 예측됩니다.
의약품 첨가제 시장 역학
최근, 제약 부문에 대한 투자가 증가하고 있기 때문에 의약품 첨가제 시장의 성장에 박차가 걸려, 향후 수년간 수요 증가가 전망되고 있습니다.
예를 들어, Congressional Budget Office(2021년)의 데이터에 따르면, 미국에서 R&D와 신약 도입에 대한 지출은 지난 20년간 상당히 증가하고 있습니다. Pharmaceutical Research and Manufacturers of America(PhRMA) 회원사의 의약 연구 개발에 대한 민간 투자는 1980년에 약 50억 달러, 2000년에는 380억 달러였지만, 2019년에는 약 830억 달러에 달했습니다.
또한 유럽과 같은 주요 지역에서는 강력하고 경쟁이 심한 제약 산업 시장이 존재합니다. 유럽위원회(2020년)의 데이터에 따르면, 의약품 제조업체는 2019년 연구 투자에 370억 유로의 최대 기여를 하고 있습니다.
유럽의 Health Emergency Response Authority(HERA)와 같은 당국의 존재는 첨가제를 포함한 의약품의 연구, 제조 및 개발에 대한 투자를 통해 전반적인 의료 인프라를 강화하는 데 도움이 됩니다.
Atradius Industry Trends Pharmceuticals(2022년)의 숫자에 따르면 인도와 같은 아시아태평양의 주요 개발 도상국에서는 유통이 인도의 제약 제조업체에게 연구 개발 비용을 결정적으로 강화하도록 자극했습니다. 게다가 2020년 공급망의 혼란으로 인도의 의약품 제조업체는 의약품 활성 성분(API)과 의약품 첨가제의 현지 생산을 늘리는 데 열심입니다.
또한 China Embassy Government(2022)의 데이터에 따르면 중국의 R&D 투자는 급속히 증가하고 있습니다. National Bureau of Statistics의 예비적 추계에 따르면 2021년 R&D 지출은 14.2% 증가한 2조 7,900억 위안을 기록했습니다. 이 나라의 꾸준한 경제 회복과 혁신의 기세가 증가함에 따라 이 나라의 연구개발비는 매년 7%가 넘는 성장이 예상됩니다.
다양한 국가의 의약품 부문에 대한 투자 증가는 보다 많은 의약품 제조에 대한 수요를 촉진하고 결과적으로 2024-2030년의 예측 기간에 의약품 첨가제 시장을 견인할 전망입니다.
그러나 첨가제와 관련된 오염과 부작용의 위험, 신규 첨가제 개발에 드는 높은 비용 등이 의약품 첨가제 시장의 성장을 제한하는 주요 요인으로 작용할 수 있습니다.
의약품 첨가제 시장의 부문 분석
의약품 첨가제 시장의 기능성 부문에서는 바인더 카테고리가 2023년에 큰 수익 점유율을 차지할 것으로 예측됩니다. 이 제품 카테고리의 급성장은 바인더의 다양한 용도와 조사 기간 동안이 카테고리에서 수행되는 제품 개발 활동으로 인한 것입니다.
의약품 정제화는 바인더에 크게 의존합니다. 바인더는 분말의 응집성과 유연성을 높이기 위해 사용되어 정제의 가공성을 향상시키고 제조 중에 정제가 파손될 위험을 줄입니다.
결합제는 분말에 응집성을 부여하기 위해 정제에 첨가되어 과립을 만드는데 필수적인 결합을 가능하게 하고, 압축될 때 정제로 알려진 콤팩트한 덩어리를 형성합니다. 즉, 바인더는 정제의 "경도"를 실현하는 데 필요합니다. 제약 산업은 포비돈, 히드록시프로파일 셀룰로오스, 미세결정질 셀룰로오스, 폴리에틸렌 글리콜, 젤라틴, 전분, 카보머, 나트륨 카르복시메틸 셀룰로오스 등 다양한 결합제를 사용합니다.
이 보고서는 세계 의약품 첨가제 시장에 대한 조사 분석을 통해 각 지역 시장 규모와 예측, 지난 3년간의 제품/기술 개발, 각 부문의 성과 및 전망 등의 정보를 제공합니다.
Pharmaceutical Excipients Market by Type (Organic Chemicals, Inorganic Chemicals, and Others), Application (Oral, Parenteral, and Topical), Functionality (Fillers, Binders, Coatings and Colorants, Flavouring Agents, Preservatives, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 due to the rising demand for pharmaceutical manufacturing owing to investments and the latest innovations in pharmaceutical research and development activities across the globe.
The Pharmaceutical Excipients market was valued at USD 9.18 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 14.12 billion by 2030. The Pharmaceutical Excipients market is growing significantly due to the rising demand for pharmaceutical manufacturing owing to investments, the latest innovations in the research and development of pharmaceuticals, and the growing number of product development activities for excipients among biotech companies and pharmaceutical firms, among others that are expected to drive the Pharmaceutical Excipients market from 2024 to 2030.
Pharmaceutical Excipients Market Dynamics:
In recent years, the increasing investments in the pharmaceutical sector is expected to spur the market growth for pharmaceutical excipients, which is expected to increase their demand in the coming years.
For example, as per data by the Congressional Budget Office (2021), spending on Research and Development and the introduction of new drugs in the US had substantially increased in the past two decades. The private investment in drug R&D among member firms of the Pharmaceutical Research and Manufacturers of America (PhRMA), was about USD 83 billion in 2019, up from about USD 5 billion in 1980 and USD 38 billion in 2000.
Also, in major regions such as Europe, there is a strong and competitive pharmaceutical industrial market. As per data by the European Commission (2020), medicine producers made the largest contribution of Euros 37 billion for research investment in 2019.
Presence of authorities such as the European Health Emergency Response Authority (HERA) helps in the strengthening the overall healthcare infrastructure through investments in research, manufacturing, and development of drugs including excipients.
Figures by the Atradius Industry Trends Pharmceuticals (2022) highlight that in major developing countries in the Asia-Pacific such as India, the pandemic spurred the Indian drug producers to crucially enhance their R&D spending. Moreover, due to the supply chain disruption in 2020, Indian drug producers are keen on increasing the local production of Active Pharmaceutical Ingredients (APIs) and pharmaceutical excipients.
Also as per data by the China Embassy Government (2022), China's investment on research and development (R&D) is growing rapidly. The country's spending on R&D climbed to 14.2 percent to 2.79 trillion RMB in 2021, according to preliminary estimates of the National Bureau of Statistics. Owing to the country's steady economic recovery and increasing innovation momentum, the country's R&D spending is expected to grow by more than seven percent every year.
The increasing investments in the pharmaceutical sector by the various countries shall propel the demand for more pharmaceutical manufacturing, thus ultimately driving the market for pharmaceutical excipients during the given forecast period from 2024 to 2030.
However, the risk of contamination and adverse reactions associated with excipients, and the high cost of development of novel excipients, among others may act as key constraints limiting the growth of the pharmaceutical excipients market.
Pharmaceutical Excipients Market Segment Analysis:
Pharmaceutical Excipients Market by Type (Organic Chemicals, Inorganic Chemicals, and Others), Application (Oral, Parenteral, and Topical), Functionality (Fillers, Binders, Coatings and Colorants, Flavouring Agents, Preservatives, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the functionality segment of the pharmaceutical excipients market, the binders category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the various applications of binders and the product development activities taking place in this category during the study period.
Pharmaceutical tableting relies heavily on binders. They are used to increase the cohesiveness and flexibility of the powder combination, hence increasing tablet processability and lowering the risk of tablet breakage during manufacturing.
Binders are added to tablet formulations to provide cohesiveness to powders, allowing the essential bonding to create granules, which when compacted form a compact mass known as a tablet. In other words, binders are required to achieve the tablet's "hardness". The pharmaceutical industry uses a wide range of binder excipients, including povidone, hydroxypropyl cellulose, microcrystalline cellulose, polyethylene glycol, gelatin, starch, carbomers, and sodium carboxymethyl cellulose, among others.
Binders are typically chosen based on prior experience, specific product requirements, or the preferences of individual scientists or manufacturing units. The fundamental criterion for selecting a binder is compatibility with other tablet components.
Additionally, the introduction of technologically improved and new products also propels the market for this category's growth. For example, in October 2021, Beneo introduced galenIQ 721, a filler binder that enhanced the flavor and stability of effervescent tablets and powders. It is a non-hygroscopic, water-soluble, and immediately compressible excipient, resulting in high content consistency and manufacturing efficiency in effervescent applications.
Therefore, owing to all the above-mentioned factors, the demand for binders upsurges, thereby the category is expected to witness considerable growth, thus contributing to the overall growth of the pharmaceutical excipients market during the forecast period.
North America is expected to dominate the overall Pharmaceutical Excipients market:
Among all the regions, North America is expected to dominate the pharmaceutical excipients market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to the growing market for pharmaceuticals, increasing investments in the research and development sector for the pharmaceutical industry along with the product development activities taking place in North America.
According to data by the National Association of Manufacturers (2021), pharmaceutical manufacturing is primarily essential to America's health and well-being and to the success of their economy.
The source further stated that the pharmaceutical and medicine manufacturing generates nearly USD 339 billion in output, directly employing an estimated 267,000 workers in the United States and supporting nearly 1.9 million more jobs across the country.
In addition as per data by the Congressional Budget Office (2021), it found that the pharmaceutical industry devoted USD 83 billion to R&D expenditures in 2019. The expenditures covered a variety of activities, including discovering and testing new drugs, developing incremental innovations, and clinical testing for safety-monitoring purposes. The US pharmaceutical industry invests on average roughly three times more in R&D as a percentage of sales than all other manufacturing industries.
The growing pharmaceutical industry along with increasing investments in R&D would spur the market demand for pharmaceutical excipients to be used for manufacturing, presenting a conducive growth environment for the pharmaceutical excipients market in the forthcoming years.
Moreover, in January 2022, Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical research, introduced Apisolex in the United States. It is a new solubility-enhancing excipient for parenteral medication formulations. This approach overcomes solubility barriers that cannot be addressed by conventional excipients or production methods.
Therefore, the interplay of all the aforementioned factors would drive the North American pharmaceutical excipients market during the forecast period.
Pharmaceutical Excipients Market key players:
Some of the key market players operating in the Pharmaceutical Excipients market include BASF SE, ADM, DuPont, Croda International PLC, Kerry, Roquette Freres, Ashland, Innophos, Associated British Foods PLC, The Lubrizol Corporation, Evonik Industries AG, Air Liquide, DSM, Merck KGaA, Eastman Chemical Company, Clariant, Clyzo, Inc., SPI Pharma, Lavina Pharmaceuticals Pvt. Ltd, Freund Corporation, and others.
Recent Developmental Activities in the Pharmaceutical Excipients Market:
Key Takeaways from the Pharmaceutical Excipients Market Report Study
Target audience who can be benefited from this pharmaceutical excipients Market Report Study
Frequently Asked Questions for the Pharmaceutical Excipients Market:
Pharmaceutical excipients are compounds other than the active pharmaceutical ingredient (API) that have been thoroughly tested for safety and are purposefully used in a medication delivery system.
The Pharmaceutical Excipients market was valued at USD 9.18 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 14.12 billion by 2030.
The Pharmaceutical Excipients market is growing significantly due to the rising demand for pharmaceutical manufacturing owing to investments, the latest innovations in the research and development of pharmaceuticals, and the growing number of product development activities for excipients among biotech companies and pharmaceutical firms, among others that are expected to drive the pharmaceutical excipients market from 2024 to 2030.
Some of the key market players operating in the Pharmaceutical Excipients market include BASF SE, ADM, DuPont, Croda International PLC, Kerry, Roquette Freres, Ashland, Innophos, Associated British Foods PLC, The Lubrizol Corporation, Evonik Industries AG, Air Liquide, DSM, Merck KGaA, Eastman Chemical Company, Clariant, Clyzo, Inc., SPI Pharma, Lavina Pharmaceuticals Pvt. Ltd, Freund Corporation, and others.
Among all the regions, North America is estimated to hold a significant revenue share in the Pharmaceutical Excipients market. This can be attributed to the growing market for pharmaceuticals, increasing investments in the research and development sector for the pharmaceutical industry along with the product development activities taking place in North America.